The bulls are back in town. November capped off an epic month, with the S&P 500 (SPX) gaining 5.4%, states Lucas Downey of Mapsignals.com.

It’s popular on Wall Street to say, “you can’t time the market.” However, just because most people are bad at it doesn’t mean the tools don’t exist to do it fairly well, states Jesse Felder of TheFelderReport.com.

I continue to wonder what people are so angry about, exclaims JC Parets of AllStarCharts.com.

An ‘Inverted Yield Curve’ occurs when short-term US government bonds pay a higher rate of interest than long-term bonds, writes Ian Murphy of MurphyTrading.com.

Inflation probably peaked for this cycle, but the Federal Reserve still has a lot of work to do, suggests retirement strategist Bob Carlson, editor of Retirement Watch.

Halozyme (HALO) has always had a story that’s easy to love, as its Enhanze drug delivery technology allows huge-selling treatments to be delivered intravenously in far less time than usual, saving tons of time, money and adding convenience, too, explains Mike Cintolo, editor of Cabot Growth Investor.

For the world to largely free itself from fossil fuels, I believe nuclear power will have to make a much larger contribution. Nuclear energy isn’t renewable, but it’s abundant and clean, with no carbon emissions, asserts Stephen Leeb, editor of Real World Investing.

Vaxart (VXRT) recently held their quarterly call and discussed their expected upcoming milestones including the selection of COVID-19 vaccine construct to be used in the UK human challenge study is expected in Q4 2022, reports John McCamant, editor of The Medical Technology Stock Letter.

All the talk this past summer and into the fall has focused on one thing: predicting peak inflation, notes Bob Lang of ExplosiveOptions.net.

I recently correctly predicted “The tightening of the Fed and the inventory correction will force commodities and Bitcoin prices to continue to decline,” states George Dagnino of Peter Dag Strategic Money Management.